SMS Pharmaceuticals Ltd (SMSPHARMA)
₹511.35
Mkt cap
₹4,789 Cr
P/E ratio
46.80
P/B
6.09
Div yield
0.08%
ROE
14.30%
ROCE
13.30%
EPS (TTM)
₹10.93
Book value
₹84
52W range
270–525
Sector
Healthcare
Price history
Previous close
SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates. [1]
NSE SMSPHARMABSE 532815
Health check
Mixed
ValuationExpensive
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−2.60% from high₹511
₹270+89.32% from low₹525
Current
₹511.35
Prev close
₹485.80
Day
+5.26%
Price performance
1D
+4.98%
1W
+23.01%
1M
+6.38%
3M
+36.13%
6M
+24.36%
1Y
+81.54%
YTD
+56.74%
Financials
Revenue, profit & margin
P/E ratio
46.8×
SMSPHARMA is 36% above the sector median of 34.4×
SMSPHARMA46.8×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 135 | 167 | 161 | 246 | 164 | 197 | 173 | 248 | 196 | 242 | 210 | 238 | 207 | |
| Expenses | 109 | 139 | 132 | 212 | 131 | 165 | 140 | 207 | 157 | 194 | 167 | 198 | 166 | |
| Operating Profit | 26 | 28 | 29 | 34 | 34 | 31 | 33 | 41 | 39 | 48 | 44 | 40 | 41 | |
| OPM % | 19% | 17% | 18% | 14% | 20% | 16% | 19% | 16% | 20% | 20% | 21% | 17% | 20% | |
| Other Income | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 4 | 3 | 2 | |
| Interest | 6 | 6 | 6 | 6 | 5 | 5 | 4 | 5 | 6 | 6 | 6 | 5 | 6 | |
| Depreciation | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | |
| Profit before tax | 13 | 15 | 17 | 22 | 22 | 20 | 22 | 29 | 24 | 34 | 31 | 27 | 27 | |
| Tax % | 31% | 21% | 26% | 26% | 25% | 29% | 24% | 30% | 23% | 26% | 26% | 23% | 26% | |
| Net Profit | 9 | 12 | 11 | 17 | 16 | 14 | 18 | 20 | 20 | 25 | 23 | 33 | 21 | |
| EPS in Rs | 1.10 | 1.38 | 1.36 | 2.04 | 1.95 | 1.66 | 2.15 | 2.29 | 2.31 | 2.70 | 2.51 | 3.49 | 2.23 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
4 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −2.77% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 31 Jul '26◦ |
| Earnings day | −2.77% |
| +1 day | −2.78% |
| +5 days | −0.53% |
| +15 days | −5.30% |
| +30 days | +9.70% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202668.07%Promoter
Promoters68.07%
FIIs1.18%0.53
DIIs0.19%2.64
Public30.55%2.10
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| SMS Pharma. | ₹511.35 | 46.77 | 4,789 | 0.08% | 21 | +2.05% | 207 | +5.56% | 13.32% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts39
PPTAug 2026TranscriptMay 2026PPTMay 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTAug 2025TranscriptJun 2025PPTJun 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptJun 2024PPTJun 2024TranscriptFeb 2024PPTFeb 2024TranscriptNov 2023PPTNov 2023TranscriptAug 2023PPTAug 2023RECAug 2023
Credit ratings6
Announcements5
Loan Agreement With The Subsidiary Of The Company 30 Oct - SMS Pharma entered a loan agreement with subsidiary SMS Peptides for up to Rs 50 crore on 30 Oct 2026.Board Meeting Intimation for Approval Of Financial Results For The Quarter Ended 30 September 2026 28 Oct - Board meets on 4 Nov 2026 to approve Q2 and H1 FY2027 unaudited results; trading window closed until 6 Nov.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Oct - Submitted Regulation 74(5) certificate for quarter and half year ended 30 September 2026.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 30 SepShareholder Meeting / Postal Ballot-Outcome of AGM 29 Sep